HopeStage
Back to all studies
CompletedNCT02352051

Atomoxetine or Methylphenidate for Executive Function in Children

About this titleRead the official source — NCT02352051
Medication studyAges 7–12ADHD
The study in practice

Understand this study

Who was this study for?

Listed age limits: 7 years to 12 years.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateFebruary 2014
Recruitment status
Completed
Enrollment listed in the registry
43
Sponsor
TC Erciyes University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Not clearly listed
Age range
From 7 Years to 12 Years
Official registry ID
NCT02352051
Official title
Show the full official title

Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is TC Erciyes University, a university.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine and methylphenidate.

Who was this study for?

Listed age limits: 7 years to 12 years.

Want to explore more studies?

Explore studies